Related Experiment Video

Updated: Jun 8, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

HER2 status and breast cancer therapy: recent advances

Debu Tripathy1

  • 1University of Texas Southwestern Medical Center in Dallas, Physicians' Education Resource 3500 Maple Ave, Suite 700, Dallas, TX 75219 USA.

F1000 Medicine Reports
|October 16, 2010
PubMed

Insights

HER2-positive breast cancer, a distinct subtype, benefits from targeted therapies. Anti-HER2 treatments significantly improve survival and offer new avenues for better outcomes in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2 gene amplification and overexpression define a distinct, aggressive breast cancer subtype.
  • This subtype (20-25% of cases) presents challenges including increased metastasis and differential drug response.
  • HER2's role has made it a key target for personalized medicine strategies.

Purpose of the Study:

  • To review the impact of HER2-targeted therapies in breast cancer.
  • To highlight advancements in modulating HER2 function for improved patient outcomes.
  • To discuss the evolving landscape of HER2-targeted agents.

Main Methods:

  • Review of clinical data and therapeutic strategies targeting HER2.
  • Analysis of the efficacy of anti-HER2 monoclonal antibodies.
  • Evaluation of emerging agents including tyrosine kinase inhibitors and signal transduction modulators.

Main Results:

  • Anti-HER2 monoclonal antibodies have substantially improved survival in advanced and early-stage HER2+ breast cancer.
  • Newer agents demonstrate significant clinical activity, further enhancing treatment efficacy.
  • Targeted therapies offer improved curability and quality of life for HER2+ breast cancer patients.

Conclusions:

  • Targeting HER2 represents a successful paradigm in rationally targeted therapy and personalized medicine.
  • Continued development of novel HER2-directed agents promises further improvements in breast cancer treatment.
  • Pharmacological modulation of HER2 function is critical for advancing breast cancer care.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...